Oral WegovyNovo Nordisk—FDA approves oral Wegovy (semaglutide 25 mg) as first oral GLP-1 for obesityOral WegovyNovo Nordisk—Oral Wegovy surpasses 3 million prescriptions in five months following January 2026 launchWegovy (semaglutide)Novo Nordisk—FDA approves Wegovy pill, oral semaglutide 25 mg, for weight managementNovo Nordisk—Novo Nordisk's US decision on haemophilia drug denecimig slips past third quarter 2026Wegovy (semaglutide)Novo Nordisk—Semaglutide's patent expires in India and many generic versions launch
Oral Wegovy
Oral semaglutide 25mg once daily; FDA approved as first oral GLP-1. OASIS-4 showed non-inferiority to injectable form.
ScalingStage 5 of 5
FDA approved Dec 2025; 3+ million prescriptions by June 2026; first oral GLP-1 for obesity.
Updated 7 Jun 2026Checked 10 Oct0 updates this week